News

News and Press Releases
Our Research Approach CF Foundation Invests up to $5M in Clarametyx Biosciences to Develop a New Anti-Bacterial Therapy 

Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.

| 2 min read
Our Research Approach CF Foundation Invests Up to $3 Million in ViaNautis Bio to Explore a New Method to Deliver Genetic Therapies to People With CF

ViaNautis’ non-viral delivery mechanism, polyNaut®, aims to improve delivery of genetic therapies to the cells of people with CF. 

| 2 min read
Diversity, Equity, and Inclusion | Our Research Approach CF Foundation Awards Advance Improvements in CF Newborn Screening

Since 2011, the Foundation has awarded $2.5 million across 35 different projects to improve cystic fibrosis newborn screening across the country.

| 4 min read
Our Research Approach CF Foundation Provides Up to $3.9M to TB Alliance to Further Develop an NTM Drug

The Cystic Fibrosis Foundation is providing additional funds to TB Alliance to advance the development of a compound that could be used to treat infections caused by nontuberculous mycobacteria.

| 2 min read
Our Research Approach Cystic Fibrosis Foundation Commits Up to $15.5M in Additional Funding for Potential Enzyme Therapy

Funding will support clinical trials for therapy that could help improve digestion in people with CF

| 3 min read
Our Research Approach CF Foundation Invests Up to $2 Million in Nanite Inc. to Explore a New Method to Deliver Genetic Therapies to the Lung

Delivery of genetic therapies to affected tissues is a key challenge to developing new treatments for people with cystic fibrosis. In addition to investing in viral delivery and lipid nanoparticles, the Cystic Fibrosis Foundation is looking at the potential of a relatively new approach to delivery using an exceptionally small synthetic molecule called a polymer nanoparticle.

| 2 min read
Our Research Approach CF Foundation Invests Up to $3.5M in Gensaic for Novel Gene Delivery Method

The Cystic Fibrosis Foundation’s investment will go toward conducting preclinical research on a novel gene delivery vehicle. If successful, this gene delivery method could overcome some of the biggest challenges to delivering a gene therapy into the lung cells of people with cystic fibrosis.

| 2 min read
About the CF Foundation | Our Research Approach CF Foundation Provides Additional Funding to Carmine Therapeutics for Early-Stage Research Into Potential Genetic Therapy

The Cystic Fibrosis Foundation is providing up to $5 million to develop a method to deliver a healthy copy of the CFTR gene into the lung cells of people with CF that is unlikely to trigger an immune system response.

| 4 min read
Our Research Approach CF Foundation Awards $1 Million to Felix Biotechnology to Develop Novel Phage Therapy

The Foundation’s award will support preclinical studies of a potential phage therapy to treat resistant Pseudomonas infections.

| 2 min read
About the CF Foundation | Our Research Approach CF Foundation Exceeds Initial $100M Infection Research Initiative Funding

This milestone was reached nearly two years ahead of the initiative’s five-year commitment. However, the Foundation aims to continue to support infection research at the same pace as it has in the past three years.

| 7 min read